Coronary artery diseaseUsefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease
Section snippets
Methods
This was a prospective, randomized, placebo-controlled trial performed in patients with baseline CKD undergoing elective coronary angiography and/or other intervention. From April 2006 to March 2008, 1,542 patients underwent planned coronary angiographic procedures at our institution. Of these, 551 patients had a preangiographic estimated creatinine clearance <60 ml/min—evaluated by applying the Cockcroft-Gault formula19—and were considered eligible for inclusion in our study. Exclusion
Results
The median age for the entire study cohort was 75 years (interquartile range 71 to 81). Mean baseline estimated creatinine clearance was 46 ± 10 ml/min and 8% of patients had severe renal impairment with estimated creatinine clearance <30 ml/min. There were no significant differences in baseline clinical, biochemical, and procedural characteristics between the atorvastatin and placebo groups (Table 1).
Mean creatinine values are listed in Table 2. No differences were found in baseline and
Discussion
In this prospective, randomized trial of 304 patients with moderate to severe CKD who underwent coronary angiographic procedures and were pretreated with intravenous hydration and oral NAC, prophylactic addition of short-term high-dose atorvastatin did not determine a further decrease of CIN occurrence compared to the placebo group (10% vs 11%, respectively). This finding was consistent in the entire prospectively defined higher-risk subgroup. Furthermore, no significant differences were found
References (30)
- et al.
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention
J Am Coll Cardiol
(2004) - et al.
Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality
Am J Med
(1997) - et al.
Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention
J Am Coll Cardiol
(2008) - et al.
Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiographyThe Recovery study
J Am Coll Cardiol
(2006) - et al.
Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions
Am J Med
(2005) - et al.
Prevention of radiocontrast-medium–induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial—a randomized controlled study
Am Heart J
(2008) - et al.
Acetylcysteine and contrast agent-associated nephrotoxicity
J Am Coll Cardiol
(2002) - et al.
Contrast nephropathy: review focusing on prevention
J Am Coll Cardiol
(2004) - et al.
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study
J Am Coll Cardiol
(2008) - et al.
Managing dyslipidemia in chronic kidney disease
J Am Coll Cardiol
(2008)